UPDATE -- Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020
Alimera Sciences (NASDAQ: ALIM) announced that CEO Rick Eiswirth will present a corporate overview at the H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference on September 15, 2020, at 3:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alimera Sciences (NASDAQ: ALIM) announced that CEO Rick Eiswirth will present a corporate overview at the H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference on September 15, 2020, at 3:30 PM ET. Interested parties can listen live via an online sign-up. An archived presentation will be available on Alimera's website starting September 16. Additionally, Eiswirth will conduct virtual one-on-one meetings from September 14-16, 2020, with scheduling available through conference coordinators.
Details
News Market Reaction – ALIM
The recorded move for ALIM in the trading session of this news was +3.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announces that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference on Tuesday September 15, 2020 at 3:30 PM ET. To listen to the conference live, please sign up at https://wsw.com/webcast/hcw7/alim/1592203.
An archived presentation will be available from September 16th on the Alimera website at https://investors.alimerasciences.com/alim/corporate_documents?type=100510&template=most_recent_redirect
In addition, Mr. Eiswirth is available for virtual one-on-one meetings from September 14 – 16, 2020. To schedule a meeting please contact the conference coordinator at meetings@hcwco.com.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com | For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.